免疫细胞及炎症因子对晚期肺癌一线化疗效果的预测价值

doi:10.3969/j.issn.1671-7171.2024.05.030

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1271 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】This study aims to explore the predictive value of T lymphocyte subsets, tumor-infiltrating lymphocytes (Tils), and inflammatory markers on the effectiveness of first-line chemotherapy in advanced lung cancer.【Methods】Serum levels of interleukin 1α (IL-1α), IL-6, IL-17, and interferon-gamma (INF-γ), as well as the proportions of T lymphocyte subsets including CD4⁺T cells, CD8⁺T cells, regulatory T cells, CD57⁺ cells, Granzyme B⁺ cells, and CD45RO⁺ cells were measured in 98 newly diagnosed patients with stage Ⅲ/Ⅳ non-small cell lung adenocarcinoma. All patients received a chemotherapy regimen of paclitaxel injection and cisplatin for four cycles. Treatment effectiveness was assessed post-treatment, and patients were categorized into the responsive and non-responsive groups. Factors influencing the non-responsiveness and potential biomarkers for predicting treatment outcomes were analyzed.【Results】Out of 98 patients, 69 were responsive to chemotherapy, while 29 were non-responsive. Non-responsive patients had a higher proportion of lymph node metastasis, and higher levels of regulatory T cells and IL-1α expression (P<0.05), while their proportions of CD57⁺ and CD45RO⁺ cells were lower than those in the responsive group (P<0.05). Multivariate stepwise logistic regression analysis indicated that high levels of regulatory T cells and IL-1α were risk factors for ineffective chemotherapy response (P<0.05), whereas CD57⁺ and CD45RO⁺ cells were protective factors (P<0.05). Receiver operating characteristic (ROC) curve analysis showed sensitivities of 82.76%, 86.21%, 89.66%, and 93.10% for regulatory T cells, CD57⁺ cells, CD45RO⁺ cells, and IL-1α levels, respectively. The combined sensitivity, specificity, and area under the curve (AUC) of regulatory T cells, CD57⁺ cells, CD45RO⁺ cells, and IL-1α levels were 82.76%, 97.10%, and 0.957, respectively.【Conclusion】T lymphocyte subsets, Tils, and inflammatory markers are closely related to the treatment outcomes of advanced lung cancer and can serve as sensitive indicators for predicting therapeutic efficacy.

Key words： Lung Neoplasms T-Lymphocyte Subsets Chemokines/BL Drug Therapy Treatment Outcome

Received: 27 December 2023

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Chao
	HU Zhiqing
	WU Yabin

Cite this article:

LU Chao,HU Zhiqing,WU Yabin. Predictive Value of Immune Cells and Inflammatory Markers on the Efficacy of First-Line Chemotherapy in Advanced Lung Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 750-753.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.05.030 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I5/750

[1] RAMOS R, MACÍA I, NAVARRO-MARTIN A, et al. Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery[J].BMC Pulm Med, 2021, 21(1):75-88.
[2] WU F Y, FAN J, HE Y Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer[J].Nat Commun,2021, 12(1):2540-2548.
[3] LIU Z C, WANG T T, SHE Y L, et al. N⁶-methyladenosine-modified circIGF₂BP₃ inhibits CD8⁺ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L₁ in non-small cell lung cancer[J].Mol Cancer,2021, 20(1):105-112.
[4] ZHANG L B, CHEN Y H, WANG H, et al. Massive PD-L1 and CD8 double positive Tils characterize an immunosuppressive microenvironment with high mutational burden in lung cancer[J].J Immunother Cancer,2021, 9(6):2356-2369.
[5] DAOU H N. Exercise as an anti-inflammatory therapy for cancer cachexia: a focus on interleukin-6 regulation[J].Am J Physiol Regul Integr Comp Physiol,2020, 318(2):296-310.
[6] 陆舜,虞永峰,纪文翔.2015年肺癌诊疗指南:共识和争议[J].解放军医学杂志,2016,41(1):1-6.
[7] 王书航,王洁. 2018年V3版NCCN非小细胞肺癌指南更新要点解读[J].华西医学,2018,33(4):388-392.
[8] 张百红,岳红云.实体瘤疗效评价标准简介[J].国际肿瘤学杂志,2016,43(11):845-847.
[9] SUN C C, ZHU W, LI S J, et al. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway[J].Genome Med,2020, 12(1):77-86.
[10] WEI X Y, GU L, HENG W. Tlymphocytes related biomarkers for predicting immunotherapy efficacy in non-small cell lung cancer[J].Oncol Lett,2021, 21(2):89-97.
[11] LIU F J, LI L H, LAN M, et al. Key factor regulating inflammatory microenvironment, metastasis, and resistance in breast cancer: interleukin-1 signaling[J].Mediators Inflamm,2021, 23(1):778-786.
[12] 张丽柯,马磊,史芳瑜,等.胃癌组织细胞程序性死亡配体1表达情况和CD8⁺肿瘤浸润T淋巴细胞密度及其与患者临床病理特征和预后的关系研究[J].中国全科医学,2022,25(18):2262.
[13] 姜俊,张瑞,杨安钢,等.轴突导向蛋白4B(SEMA4B)通过增加肿瘤组织巨噬细胞和调节性T细胞促进肺癌细胞生长[J].细胞与分子免疫学杂志,2020,36(1):56-62.
[14] CREELAN B C, WANG C, TEER J K, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J].Nat Med,2021, 27(8):1410-1418.
[15] CHIU J W, BINTE HANAFI Z, CHEW L C Y, et al. IL-1α processing, signaling and its role in cancer progression[J].Cells,2021,10(1):92-98.